Strong nursing operator, serious legal cloud
- PACS operated 323 facilities across 17 states with about 35,500 total beds as of March 31, 2026.
- Q1 2026 patient and resident service revenue rose 11.2% to $1.4 billion.
- Management raised full-year 2026 adjusted EBITDA guidance to $605 million to $625 million.
- The board approved a $250 million share repurchase authorization, giving PACS another use for cash.
- The main risk is still the unresolved DOJ and SEC investigations into billing, reporting, and controls.
Good quarter, hard question
PACS had a strong start to 2026. Revenue kept growing, management raised full-year adjusted EBITDA guidance by $50 million, and the company restarted deal activity with new facility additions and one real estate purchase in Q1.
The bull case is simple. PACS buys weaker skilled nursing facilities, invests in staff and systems, and tries to move them toward higher occupancy and higher-acuity care. The company says guidance now excludes future M&A, so the raised profit outlook points to better core performance rather than just more deals.
The bear case is also simple. DOJ and SEC investigations remain unresolved. Management said the matters are moving in the normal course, but gave no estimate for timing or cost. A large fine, billing restriction, or control failure could erase a lot of the operating progress.
This is why PACS scores well on operating performance but weaker on financial health and sentiment. The business is working, but investors still need proof that the legal and control issues will not become a balance sheet problem.
Buy beds, improve care
PACS makes most of its money from patient and resident care. More than 97% of revenue comes from skilled nursing operations. Its payors are mainly Medicare, Medicaid, and third-party insurers such as commercial health plans.
The company looks for facilities that are underperforming. After buying them, PACS spends roughly three years improving clinical teams, technology, local leadership, and the building itself. The goal is to raise occupancy, handle more complex short-term patients, and earn better revenue per bed.
PACS runs a decentralized model. Local facility leaders make many day-to-day calls, while PACS Services provides shared back-office tools and support. That can help the company scale, but it also makes internal controls and billing rules very important.
PACS is also buying or securing rights to more of its facility real estate. As of Q3 2025, it owned, had purchase options, or had future rights to nearly half of the properties it operated. That can add long-term value, but it also uses cash that might otherwise go to debt, deals, or buybacks.
Facilities at different stages
Skilled nursing facilities
This is the core business and provides more than 97% of revenue. PACS focuses on post-acute care, including patients who need nursing or rehab after a hospital stay.
New facilities
These are facilities bought or built less than 18 months before the measurement date. They usually start with lower occupancy and need investment before they show the PACS model.
Ramping facilities
These facilities are 18 to 36 months into PACS ownership. This is where the company expects care quality, occupancy, and skilled patient mix to improve.
Mature facilities
These have been in the portfolio for more than 36 months. Mature facilities had 95% occupancy as of Q3 2024, versus 83% for New facilities.
Assisted and independent living
PACS also operates assisted living and independent living facilities. This is much smaller than skilled nursing, but it can add local scale in markets where PACS already operates.
Facility real estate
The company is increasing ownership or rights to the buildings it operates. In Q1 2026, PACS spent $86.5 million on real estate acquisitions.
One reportable segment
PACS reports as one segment. The mix below uses the company context that more than 97% of revenue comes from skilled nursing operations, with the rest in assisted living, independent living, and other care settings.
What could break
DOJ billing outcome
High impact · Medium oddsThe DOJ investigations include possible False Claims Act issues tied to Medicare billing, patient referrals, COVID-19 waiver practices, and possible false statements under HIPAA. PACS says it is cooperating, but it cannot estimate timing or outcome. A bad result could bring fines, repayments, monitoring, or limits on billing practices.
SEC and control findings
High impact · Medium oddsThe SEC is investigating accounting, financial reporting, disclosure, and internal controls. PACS also disclosed material weaknesses in internal control over revenue recognition for year-end 2025. If the company cannot fix these controls, investors may keep discounting the stock even if operations improve.
Acquisition discipline slips
Medium impact · Medium oddsThe growth model depends on buying weak facilities at good prices and improving them over time. Management has talked about a strong M&A pipeline and possible larger portfolios. Bigger deals can add growth, but they also raise integration risk and may require more cash or debt.
Government payor pressure
High impact · Medium oddsMost PACS revenue comes from care paid by Medicare, Medicaid, and other third-party payors. Rate cuts, tougher audits, or denied claims can hurt revenue and cash flow. This risk matters more because the company is already under billing-related investigations.
Capital allocation under a cloud
Medium impact · Medium oddsThe new $250 million buyback can help shareholders if the stock is cheap. But PACS also needs cash for acquisitions, real estate, facility upgrades, and possible legal costs. If management buys stock before the legal outcome is clear, the move could look poorly timed.
In one breath
What does PACS Group do?
PACS Group operates post-acute care facilities, mainly skilled nursing facilities. It buys underperforming facilities and tries to improve occupancy, care quality, and profit over several years.
Why are DOJ and SEC investigations important for PACS stock?
They could lead to fines, repayments, control changes, or limits on billing practices. The size and timing are not known, which makes the stock harder to value.
What changed after Q1 2026?
PACS raised full-year adjusted EBITDA guidance to $605 million to $625 million and announced a $250 million share repurchase authorization. The legal investigations, however, did not get a clear resolution.
How does PACS measure whether acquisitions are working?
It groups facilities by age: New, Ramping, and Mature. The model looks better when older facilities show higher occupancy, better quality scores, and stronger skilled patient mix.